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Cognitively normal women with
Alzheimer’s disease proteinopathy show
relative preservation of memory but not of
hippocampal volume
Jessica Z. K. Caldwell1* , Jeffrey L. Cummings1,2, Sarah J. Banks1,3, Sebastian Palmqvist4,5† and Oskar Hansson4,6†

Abstract
Background: We examined interactive effects of sex, diagnosis, and cerebrospinal fluid (CSF) amyloid beta/phosphorylated
tau ratio (Aβ/P-tau) on verbal memory and hippocampal volumes.
Methods: We assessed 682 participants (350 women) from BioFINDER (250 cognitively normal [CN]; and 432 symptomatic:
186 subjective cognitive decline [SCD], 246 mild cognitive impairment [MCI]). General linear models evaluated effects of
Alzheimer’s disease (AD) proteinopathy (CSF Aß/p-tau ratio), diagnosis, and sex on verbal memory (ADAS-cog 10-word
recall), semantic fluency (animal naming fluency), visuospatial skills (cube copy), processing speed/attention functions
(Symbol Digit Modalities Test and Trail Making Part A), and hippocampal volumes.
Results: Amyloid-positive (Aβ/P-tau+) CN women (women with preclinical AD) showed memory equivalent to amyloidnegative (Aβ/P-tau−) CN women. In contrast, Aβ/P-tau+ CN men (men with preclinical AD) showed poorer memory than
Aβ/P-tau− CN men. Symptomatic groups showed no sex differences in effect of AD proteinopathy on memory. There was
no interactive effect of sex, diagnosis, and Aβ/P-tau on other measures of cognition or on hippocampal volume.
Conclusions: CN women show relatively preserved verbal memory, but not general cognitive reserve or preserved
hippocampal volume in the presence of Aβ/P-tau+. Results have implications for diagnosing AD in women, and for clinical
trials.
Keywords: Subjective cognitive decline, Mild cognitive impairment, Hippocampus, Sex, Women, Verbal memory

Background
Memory differs between women and men in ways that
may meaningfully impact the detection and course of Alzheimer’s disease (AD). In particular, women have verbal
memory strengths that appear to be sustained early in the
disease, despite measurable pathological changes, including fluorodeoxyglucose positron emission tomography
(FDG PET) abnormalities [1], hippocampal volume (HV)
loss [2], and amyloid beta (Aβ) protein accumulation as
shown by a positive amyloid PET scan [3, 4]. This early
preserved memory may delay diagnosis [5], which is
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troubling given evidence that women—and particularly
those with risk factors such as Apolipoprotein ε4 (APOE
ε4) genotype—may decline faster than men, once ADrelated cognitive decline has begun [6–9]. The exact timing of women’s memory changes in AD remains unknown
and a topic of interest [10].
Memory advantages in women throughout the lifespan
could relate to a variety of etiological factors (e.g., [9, 11–
14]). Proximally, preservation of memory is expected to be
reflected in resilience in neural structures and functions
that subserve healthy memory. Although memory relies
on a complex network of neural regions interacting effectively, the central role of the hippocampus in episodic
memory (for a review, see [15]) and in AD [16] makes this
structure a natural candidate for underlying neural resilience. Specifically, the hippocampus is critical for memory
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consolidation, and damage to the hippocampus can lead
to decreased ability to learn and recall new information
[15]. In AD, the hippocampus is impacted by pathology
early in the disease course, with neurofibrillary tangle
buildup beginning in the cornu ammonis 1 (CA1) and
subiculum regions and progressing throughout the hippocampus in a predictable fashion [16].
Previous work from our group has built preliminary
support for relatively preserved total and right hippocampal volume (HV) [3] and right subiculum subfield
volume [17] in women. Specifically, with a trend-level
finding, our data suggested that sex moderated the
effects of diagnosis and amyloid PET positivity on HV.
In women, positive amyloid PET related to smaller HV
only at the mild cognitive impairment (MCI) stage, but
not in cognitively normal women. The pattern in men
was similar, but the differences were not significant [3].
When we examined these findings by hippocampal subfield, we replicated the effect only within the right subiculum [17].
Importantly, if sex relates to a time-limited preservation of memory and/or HV in AD, analyses of sex effects
should consider both diagnostic trajectory (i.e., normal
cognition to MCI to dementia) and presence of biomarkers such as brain amyloid and tau measured by
PET or indexed by the cerebrospinal fluid (CSF). This
process allows for higher certainty that sex effects are
occurring in AD and not general to non-AD cognitive
impairment.
Work on sex differences in AD has been done with
large, well-characterized study samples, and especially in
one study population (the Alzheimer’s Disease Neuroimaging Initiative [ADNI]). However, a key step in understanding sex differences in AD is exploring whether
findings within ADNI replicate in different samples and
with different measures.
The current investigation sought to examine whether
the effects of AD proteinopathy on memory and hippocampal volume differ based on sex in the Swedish BioFINDER cohort. BioFINDER offers advantages in that it
includes a clinically representative sample of patients who
were consecutively referred to participating memory
clinics and control participants recruited from an ongoing
population-based study (the Malmö Diet and Cancer
study) [18]. Both groups on average have levels of education more typical of an aging population than in some
other large study samples [19] and were scanned on the
same magnetic resonance (MR) scanner. BioFINDER also
includes measures of other cognitive domains, including
visuospatial skills, attention, and processing speed skills,
allowing for assessment of the specificity of effects to the
memory domain. Altogether, these advantages position
the BioFINDER [20] sample well to identify associations
between biomarkers of pathological change and cognition.
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Based on our prior results [3, 17], we hypothesized
that women would show early relative preservation of
memory and HV, such that these variables would be impacted less by AD proteinopathy (Aβ/P-tau+) in CN
women than in CN men. In other words, women, but
not men, with preclinical AD would show early preservation of these variables. We hypothesized this effect
would be specific to memory and not generalized to
other cognitive domains. We further hypothesized that
at the symptomatic stage, Aβ+ women would no longer
show relative preservation of memory and HV, and no
sex differences would be observed.

Methods
Participants

Participants were selected from the Swedish BioFINDER
study, which is a prospective, longitudinal study examining disease mechanisms in AD and other neurodegenerative disorders using several fluid and imaging
biomarkers (see http://biofinder.se for more information
about the study design). For the present study, we included participants with CSF and MRI data from the
healthy elderly control cohort (n = 250) and all nondemented patients that had been referred to participating memory clinics due to cognitive symptoms (n = 432).
The CN elderly participants were consecutively enrolled from a population-based cohort in the South of
Sweden (Malmö Diet and Cancer Study [18]). The inclusion criteria were (1) age ≥ 60 years old, (2) Mini-Mental
State Examination (MMSE) [21] score of 28–30 points,
and (3) fluent in Swedish. The exclusion criteria were (1)
presence of subjective cognitive impairment, (2) significant neurologic disease (for example, stroke, Parkinson’s
disease, multiple sclerosis), (3) severe psychiatric disease
(for example, severe depression or psychotic syndromes),
and (4) dementia or mild cognitive impairment (MCI).
The patients with cognitive symptoms (“symptomatic
patients”) had all been referred to one of three participating memory clinics in the south of Sweden, mostly
from primary care, and consecutively enrolled in BioFINDER based on the following inclusion and exclusion
criteria: (1) perceived cognitive decline, (2) did not fulfill
Diagnostic and Statistical Manual of Mental Disorders,
5th Edition (DSM-5) [22] criteria for Major Neurocognitive Disorder (dementia), as assessed by a memory clinic
physician, (3) had a MMSE score of 24 to 30 points, (4)
were aged 60 to 80 years, and (5) were fluent in Swedish.
The exclusion criteria were (1) cognitive impairment
that could be explained by another condition (other than
prodromal dementia), such as brain tumor, (2) severe
somatic disease, and (3) refusing lumbar puncture or
neuropsychological testing.
The patients were further categorized as having subjective cognitive decline (SCD) (n = 186) or MCI (n =
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246). The MCI classification was based on the results of
a comprehensive neuropsychological battery and the
clinical assessment of a senior neuropsychologist and
two physicians [23]. Patients with composite z-scores of
≤ − 1.5 standard deviations (SD) in at least one cognitive
domain were classified as MCI (at least two different
tests were used for each cognitive domain). In agreement
with the DSM-5 criteria for mild neurocognitive disorders, all subjects with z-scores of − 1 to − 1.5 were individually assessed by the neuropsychologist and classified
as MCI if their premorbid ability or individual test
scores within each domain indicated a significant cognitive decline. Among the MCI participants, 75% were
categorized as amnestic MCI and 25% as non-amnestic
MCI. The participants with cognitive complaints who
did not fulfill the criteria for MCI or dementia were classified as having SCD. Neuropsychological test measures
incorporated in the following statistical analyses were
not included in the battery used to determine diagnosis.
The study was approved by the ethical review board in
Lund, Sweden, and all participants gave their written informed consent.
CSF analysis and classification of Aβ/P-tau status

Lumbar puncture (LP) and CSF procedures followed a
previously described protocol [22]. CSF Aβ42 and phosphorylated tau (P-tau) were analyzed using the Elecsys
immunoassays on a cobas e601 analyzer at the Clinical
Neurochemistry Laboratory, University of Gothenburg,
Sweden.
Aβ/P-tau positivity was defined based on a previously defined CSF cut-off (phosphorylated tau/Aβ42 ratio ≥ 0.022).
This cutoff has been validated against FDA-approved visual
reads of Aβ PET scans with 90% agreement [24].
MRI procedures and hippocampal volume

All participants were examined using the same MR scanner
(3 Tesla Siemens Tim Trio). The MR scanning and imaging
procedures have been described previously [25]. FreeSurfer
software (version 5.3) was used to extract data for the total
intracranial volume and total HV (left and right).
Memory function

The 10-word list from the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog) was used
to test memory function [26]. After three learning trials
of 10 words (immediate recall) and a distraction task
(naming objects and fingers), the participants were asked
to recall the 10 words. The number of omissions on the
delayed recall task (i.e., total possible recalled—total
recalled) constituted the final test score. Commission errors were not analyzed.
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Non-memory functions

Semantic fluency was assessed using the animal naming
fluency test [27]. Visuospatial function was assessed with
a cube copying task [28] scored from 0 to 6 points [26].
Attention and speed were assessed using Trail Making
Test Part A (TMT A) [29] and the Symbol Digit Modalities Test (SDMT) [30].
Statistical analysis

Groups were compared using the Mann-Whitney Test. A p
value of < 0.05 was used to define statistical significance. Several general linear models (GLMs) were used to test the effect of sex on cognitive performance in the presence of AD
proteinopathy at different diagnostic stages. First, we examined memory function (delayed recall omissions) as the
dependent variable with the independent variables Aβ/P-tau
status, diagnostic group, sex, years of formal education, presence of at least one APOE ε4 allele, HV, and total intracranial
volume. Interaction effects were tested for Aβ/P-tau status,
diagnostic group, and sex. This model was also run using
animal naming fluency, cube copying, TMT A, and SDMT
as dependent variables. Diagnostic group was primarily stratified into CN and symptomatic patients to achieve better statistical power for the primary analyses; in secondary analyses,
the symptomatic patients were further stratified into SCD
and MCI patients. To further examine sex differences in the
effect of AD proteinopathy on memory, we ran GLMs using
delayed recall omissions as dependent variable and Aβ/P-tau,
age, and education as independent variables. This model was
tested separately for men and women in all diagnostic subgroups (primary analyses separately in CN and symptomatic
patients, and in secondary analyses with symptomatic patients stratified into SCD and MCI). Here, (Aβ/P-tau+) CN
women are referred to as women with preclinical AD, and
(Aβ/P-tau+) CN men are similarly referred to as men with
preclinical AD.
Next, sex differences in the effect of AD proteinopathy
on HV were examined in the different diagnostic groups.
Here, we used models with HV as a dependent variable
with the independent variables Aβ/P-tau, sex, diagnostic
group, age, education, presence of at least one APOE ε4
allele, and total intracranial volume. Total HV, left HV,
and right HV were used separately as dependent variables. As for the GLMs described above, interaction effects were tested for Aβ/P-tau status, diagnostic group,
and sex (as above, diagnostic group was stratified both
as CN or symptomatic patient and, in secondary analyses
as CN, SCD, or MCI). In the secondary analyses where
symptomatic patients were further stratified into SCD
and MCI, interaction effects were analyzed with MannWhitney tests due to smaller sample sizes and skewed
distributions. All statistical analysis was performed using
R version 3.4.4 (The R Foundation for Statistical
Computing).
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Results
Demographics

Of 682 participants, 350 were women, 241 were Aβ/Ptau+, and 267 were APOE ε4 carriers. Regarding diagnosis, 250 were CN and 432 had cognitive symptoms (of
which 186 had subjective and 246 objective symptoms).
Average age was 71.7 (SD = 5.5). Of CN participants, 152
were women, 67 were APOE ε4 carriers (39 women),
and 45 were Aβ/P-tau+ (29 women). Of symptomatic
patients, 198 were women, 200 were APOE ε4carriers
(90 women), and 196 were Aβ/P-tau+ (88 women). See
Tables 1 and 2 for additional demographic and descriptive information.
Among CN participants, Mann-Whitney tests showed that
age and education did not differ by amyloid status (age: W =
3955.5, p = 0.13; education: W = 4433.0, p = 0.68), but a
greater percentage of Aβ/P-tau+ versus Aβ/P-tau− CN individuals were APOE ε4 carriers (W = 2482.0, p < 0.001).
Mann-Whitney tests also revealed CN women were older
(W = 6439.5, p = 0.05), but CN men and women did not differ in education level (W = 7969.0, p = 0.35) or number of
APOE ε4 carriers (W = 7490.0, p = 0.57) (see Table 1).
Within symptomatic participants, Mann-Whitney tests
showed that Aβ/P-tau+ individuals were older (W = 17,
639.0, p < 0.001) and were more likely to be APOE ε4 carriers
(W = 12,647.0, p < 0.001). Symptomatic Aβ/P-tau+ versus
Aβ/P-tau− individuals did not differ in education level
(W = 23,862.0, p = 0.36). Mann-Whitney tests also revealed
men and women with cognitive symptoms did not differ in
education level (W = 21,386.0, p = 0.30) or number of APOE
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ε4 carriers (W = 23,418.0, p = 0.69), but men were older
(W = 25,686.0, p = 0.05) (see Table 1).
Secondary Mann-Whitney analyses examining differences
within SCD and MCI individuals showed that within SCD,
Aβ/P-tau+ individuals were older (W = 2852.5, p < 0.01),
more likely to be APOE ε4 carriers (W = 2345.0, p < 0.001),
and had lower education levels (W = 4576.5, p = 0.015).
Mann-Whitney tests revealed men and women with SCD
did not differ in education level (W = 414,105.0, p = 0.68) or
number of APOE ε4 carriers (W = 4382.00, p = 0.53), but
men were older (W = 5094.5, p = 0.03). For MCI individuals,
Aβ/P-tau+ individuals were older (W = 5778.0, p < 0.01),
more likely to be APOE ε4 carriers (W = 3743.0, p < 0.001),
and had higher education levels (W = 6019.5, p = 0.03).
Mann-Whitney tests showed men and women with SCD did
not differ in education level (W = 6814.0, p = 0.83), number
of APOE ε4 carriers (W = 6990.0, p = 0.62), or age
(W = 7455.5, p = 0.67) (see Table 2).
Interactive effects of sex, diagnosis, and amyloid status
on delayed verbal recall

The GLM with sex, diagnosis (CN or symptomatic), Aβ/
P-tau+, and their interactions predicting delayed recall
omissions on the ADAS word recall task showed a significant three-way interaction of Aβ/P-tau+, diagnosis,
and sex (p < 0.001) as well as a two-way interaction of
Aβ/P-tau+ and sex (p = 0.008). These interactions were
observed in a model including age, education, APOE ε4
status, and total HV as covariates (Table 3). A secondary
analysis that grouped diagnoses as CN, SCD, or MCI

Table 1 Means and standard deviations by diagnostic group (cognitively normal or symptomatic), sex, and Aβ/P-tau status for
demographics; memory and global cognitive scores, hippocampal and total intracranial volumes; and number of APOE ε4 carriers
Cognitively normal (CN)
Men

Symptomatic patients
Women

Men

Women

Aβ/P-tau+

Aβ/P-tau−

Aβ/P-tau+

Aβ/P-tau−

Aβ/P-tau+

Aβ/P-tau− Aβ/P-tau+

Aβ/P-tau−

(N = 16)

(N = 82)

(N = 29)

(N = 123)

(N = 108)

(N = 126)

(N = 110)

72.40 (4.58) b

74.38 (4.34) b

74.03 (5.31) b

72.43 (5.18) a,b 69.84
(5.61) a,b

71.12 (5.05)
11.51 (3.31)

b

(N = 88)
a,b

69.08 (5.68) a,b

Age

74.38 (4.40)

Education

14.12 (4.29)

12.17 (3.58)

11.97 (4.23)

12.08 (3.30)

11.65 (3.58)

11.63
(3.69)

ADAS Delayed Word
Recall Omissions (/10)

3.31 (2.39)

2.12 (1.63)

2.07 (2.17)

1.74 (1.91)

6.00 (2.39)

4.90 (2.37) 6.50 (2.40)

3.50 (2.46)

MMSE total score

28.69 (0.87)

29.09 (0.98)

29.17 (0.76)

28.91 (0.99)

27.19 (1.80)

28.11
(1.78)

28.31 (1.57)

Total intracranial volume 1.7 × 106
(1.5 × 105)

1.7 × 106
(1.3 × 105)

1.5 × 106
(9.7 × 104)

1.5 × 106
(1.1 × 105)

1.7 × 106
(1.2 × 105)

1.7 × 106 1.5 × 106
(1.4 × 105) (1.2 × 105)

1.5 × 106
(1.2 × 105)

Total hippocampal
volume

7.8 × 103
(1.0 × 103)

7.7 × 103
(1.1 × 103)

7.0 × 103
(8.9 × 102)

7.1 × 103
(9.1 × 102)

6.8 × 103
(1.1 × 103)

7.4 × 103 6.3 × 103
(1.3 × 103) (1.1 × 103)

7.1 × 103
(1.1 × 103)

APOE ε4 carriers

12 a

16

16 a

23 a

76 a

a

34 a

27.1 (1.78)

63 a

12.18 (3.28)

27

a

Abbreviations: Aβ/P-tau+ amyloid beta/P-tau positive, ADAS Alzheimer’s Disease Assessment Scale, APOE apolipoprotein E, MMSE Mini-Mental State Examination
a
Differs by Aβ/P-tau+ within diagnostic group, p < 0.001
b
Differs by sex within diagnostic group, p < 0.05
Significant differences in these variables by Aβ/P-tau status and sex within each diagnostic group are indicated by superscript
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Table 2 Means and standard deviations by symptomatic diagnostic group (subjective cognitive decline or mild cognitive
impairment), sex, and Aβ/P-tau status for demographics; memory and global cognitive scores, hippocampal and total intracranial
volumes; and number of APOE ε4 carriers

Age

Subjective cognitive decline (SCD)

Mild cognitive impairment (MCI)

Men

Men

Women

Women

Aβ/P-tau+

Aβ/P-tau−

Aβ/P-tau+

Aβ/P-tau−

Aβ/P-tau+

Aβ/P-tau−

Aβ/P-tau+

Aβ/P-tau−

(N = 34)

(N = 51)

(N = 25)

(N = 76)

(N = 74)

(N = 75)

(N = 63)

(N = 34)

72.59 (5.37)

70.22 (5.46)

70.63 (4.84)

69.78 (5.69)

72.35 (5.13) a 69.59 (5.74) a 71.37 (4.88) a 69.76 (5.52) a

a,b

a,b

a,b

Education

11.71 (3.84) a 13.00 (3.59)

ADAS Delayed Word Recall
Omissions (/10)

4.12 (1.89)

3.38 (1.89)

5.06 (3.02)

4.73 (2.80)

6.91 (2.06) a

5.92 (2.10) a

7.43 (1.81) a

5.24 (2.69)

MMSE total score

28.35 (1.54)

28.92 (1.29)

27.88 (1.88)

27.74 (1.73)

26.65 (1.67)

27.56 (1.85)

26.84 (1.79)

27.62 (1.88)

6

11.60 (3.33) a 11.97 (3.30)

6

6

a

11.62 (3.49) a 10.71 (3.48) a 11.44 (3.07) a 10.47 (3.13) a

Total intracranial volume

1.7 × 10
(1.1 × 105)

1.7 × 10
(1.3 × 105)

1.5 × 10
(1.1 × 105)

1.5 × 10
(1.2 × 105)

1.7 × 10
(1.3 × 105)

1.7 × 10
(1.4 × 105)

1.5 × 10
(1.2 × 105)

1.5 × 106
(1.2 × 105)

Total hippocampal volume

7.2 × 103
(1.1 × 103)

7.7 × 103
(1.3 × 103)

6.8 × 103
(1.3 × 103)

6.7 × 103
(1.1 × 103)

6.7 × 103
(1.1 × 103)

7.2 × 103
(1.3 × 103)

6.1 × 103
(1.0 × 103)

6.6 × 103
(1.2 × 103)

APOE ε4 carriers

21

14 a

17 a

21 a

55 a

20 a

46 a

6

a

6

a

a,b

6

6

6

a

a

Abbreviations: Aβ/P-tau+ amyloid beta/P-tau positive, ADAS Alzheimer’s Disease Assessment Scale, APOE apolipoprotein E, MMSE Mini-Mental State Examination
a
Differs by Aβ/P-tau+ within diagnostic group, p < 0.05
b
Differs by sex within diagnostic group, p < 0.05
Significant differences in these variables by Aβ/P-tau status and sex within each diagnostic group are indicated by superscript

showed a similar three-way interaction of Aβ/P-tau+,
diagnosis, and sex (p = 0.01; see Table 4).
Parsing this interaction effect indicated that women but
not men showed a significant interaction between amyloid
status and diagnosis (subsample with men, p = 0.42; subsample with women, p < 0.001). Specifically, Aβ/P-tau+ did
not impact delayed recall memory in women in the CN
group (p = 0.45, adjusted for age and education), but related
to poorer memory in symptomatic women (p < 0.001). In
contrast, Aβ/P-tau+ was associated with poorer memory
performance both in CN men (p = 0.02) and in symptomatic
men (p = 0.003) adjusted for age and education (Fig. 1). A
secondary analysis, splitting the symptomatic group into
SCD and MCI, showed Aβ/P-tau+ related to poorer memory
both in female SCD (p = 0.02) and MCI (p < 0.001) and in
male SCD (p = 0.057) and MCI (p = 0.006) (see Additional file 1: Figure S1).
Interactive effects of sex, diagnosis, and amyloid status
on verbal semantic fluency, visuospatial function, and
attention/processing speed

The above models with sex, diagnosis (CN or patients with
cognitive symptoms), Aβ/P-tau+, and their interactions were
also tested for predicting performance on verbal semantic
fluency (animal naming fluency), visuospatial function (cube
copying), and attention/processing speed (TMT A and
SDMT). The models were, as for memory function, adjusted
for age, education, APOE ε4 status, and total HV. In contrast
to using memory performance as outcome, the three-way
interaction of Aβ/P-tau+, diagnosis, and sex was not significant for verbal fluency (p = 0.11), visuospatial function (p =

0.60), or attention/processing speed (TMT A, p = 0.86;
SDMT, p = 0.96).
Interactive effects of sex, diagnosis, and amyloid status
on hippocampal volume

In contrast to the memory analysis, the GLM with sex,
diagnosis, Aβ/P-tau+, and their interactions predicting
total HV did not show a significant interaction of Aβ/Ptau+, diagnosis, and sex (p = 0.91). However, diagnosis,
age, and total intracranial volume (ICV) showed significant main effects on HV. Specifically, older age was associated with smaller HV (p < 0.001), as was having
cognitive symptoms (p < 0.001). Greater total intracranial
volume was associated with greater HV (p < 0.001) (see
Table 3 for details). Similar significant main effects and
similar lack of interaction effects were seen when grouping diagnoses into CN, SCD, and MCI and when left
and right HV were examined separately (interaction: left:
p = 0.68; right: p = 0.85; total p = 0.91) (see Additional file 2 for details).

Discussion
The current study showed that women with AD proteinopathy (Aβ/P-tau+) showed no memory impairment
relative to Aβ/P-tau− women prior to self-reporting concerns about their cognition (i.e., only in the CN group).
In contrast, men with Aβ/P-tau+ performed more poorly
on the verbal memory task than Aβ/P-tau− men, regardless of whether they experienced cognitive symptoms or
not. As hypothesized, similar effects were not seen on
tests of other cognitive domains. Analyses examining
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Table 3 Results for regression models with sex, diagnosis
(cognitively normal or symptomatic), Aβ/P-tau status, and their
interactions predicting recall omissions on the ADAS word recall
task and total hippocampal volume
Variable

ADAS 10 Word Recall Omissions
Estimate

p

Intercept

0.56

0.704

Diagnosis (0 = CN, 1 = symptomatic)

2.51

< 0.001

Age

0.0088

0.61

Education

−0.107

< 0.001

Total intracranial volume (z-scored)

0.225

0.039

Sex (0 = male)

0.22

0.74

Hippocampal volume (z-scored)

−0.781

< 0.001

APOE ε4 Genotype (0 = no ε4)

0.049

0.79

CSF Aβ/P-tau positivity (Aβ/P-tau+)
(0 = not Aβ/P-tau+)

1.97

0.10

Aβ/P-tau+ × diagnosis

−0.63

0.33

Aβ/P-tau+ × sex

−4.05

0.008

Diagnosis × sex

−0.76

0.06

Aβ/P-tau+ × diagnosis × sex

2.92

< 0.001

Variable

Total hippocampal volume
Estimate

p

Intercept

10,938

< 0.001

Diagnosis (0 = CN, 1 = symptomatic)

− 547

< 0.001

Age

−82.8

< 0.001

Education

5.00

0.64

Total intracranial volume (z-scored)

0.0019

< 0.001

Sex (0 = male)

− 166

0.59

APOE ε4 Genotype (0 = no ε4)

20.7

0.81

Aβ/P-tau+ (0 = not Aβ/P-tau+)

453

0.42

Aβ/P-tau+ × diagnosis

− 401

0.18

Aβ/P-tau+ × sex

−72.1

0.92

Diagnosis × sex

77.8

0.68

Aβ/P-tau+ × diagnosis × sex

−76.0

0.84

Abbreviations: Aβ/P-tau+ amyloid beta/P-tau positivity, ADAS Alzheimer’s
disease Assessment Scale, APOE apolipoprotein E, CN cognitively normal, CSF
cerebrospinal fluid, MMSE Mini-Mental State Examination
significant p values had been bolded (p < .05)

HV showed no significant interactive effects of sex, diagnosis, and Aβ/P-tau+, and diagnosis alone of these three
factors showed a significant main effect on HV.
These results supported our hypotheses about sexbased preservation of verbal memory. Namely, Aβ/Ptau+ CN women (i.e., women with preclinical AD)
appear to have verbal memory reserve or resilience in
the presence of measurable AD-related disease burden.
This result is consistent with our and others’ work
showing that women’s memory has some early resilience
to a number of markers of AD burden, including
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abnormal brain metabolism [1], hippocampal atrophy
[2], and positive amyloid PET [3, 4]. Importantly, the
current results replicate our prior findings in a separate
sample that incorporated different measures of memory
and amyloid proteinopathy, supporting the robustness of
this finding [3]. Early verbal memory preservation may
have implications for how normal cognition is defined in
research and in clinical trials. For example, it may be
more critical when examining longitudinal or interventional outcomes to define baseline group membership
using biomarkers in combination with cognitive testing,
if women are included in the sample. From a clinical
diagnosis perspective, this finding emphasizes the importance of cognitive baseline assessment, as early
neuropsychological testing may be able to identify
women who have normal cognition yet have lost some
memory functioning over time. Employing memory assessments that are not purely verbal may also be important for increasing validity of memory assessment across
sexes.
Supplementary analyses showed that verbal memory
was not preserved in Aβ/P-tau+ women with SCD as
compared to Aβ/P-tau− women with SCD. In addition,
in the SCD group, women no longer outperformed men
in verbal memory. This pattern suggests that among
women with increased risk for AD dementia (Aβ/Ptau+), memory reserve or resilience is limited to CN
women with no cognitive concerns. This finding is consistent with studies showing that SCD is associated with
positive AD biomarkers and longitudinal cognitive decline ([for recent review on SCD, see [31]), as well as
with research showing that AD proteinopathy in the
context of SCD is a strong predictor of decline [32].
However, this finding stands in contrast to research
within the ADNI sample, showing that women outperform men on verbal memory tasks despite mild to moderate levels of AD-related burden [1, 2]. It is possible
that the current finding relates to Aβ/P-tau+ women
with SCD in the BioFINDER sample having more than a
moderate level of AD-related disease burden. Alternatively, the finding may relate to other differences between samples. Specifically, the greater education
levels—and thereby greater general cognitive reserve—in
the ADNI sample may have an impact. On the other
hand, in the BioFINDER sample, individuals with SCD
have been referred to a memory specialist due to cognitive symptoms, whereas in ADNI, individuals with SCD
reported symptoms when queried. In this context, our
findings suggest that for women seeking a memory specialist, SCD could be not only a marker of risk, but also
an indicator that subclinical memory changes are already
measurable on cognitive testing. This suggestion is in
part consistent with very recent work in other cohorts
[33, 34].
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Table 4 Results for secondary regression model with sex, diagnosis (cognitively normal, subjective cognitive decline, or mild
cognitive impairment), Aβ/Ptau status, and their interactions predicting recall omissions on the ADAS word recall task
Variable

ADAS 10 Word Recall Omissions
Estimate (CI)

p

Intercept

−.986 (−2.14–4.90)

0.454

Diagnosis (1 = CN, 2 = SCD, 3 = MCI)

1.75 (1.44–2.07)

< 0.001

Age

0.03 (−0.00–0.60)

0.035

Education

−0.07 (−0.12 to − 0.03)

< 0.001

Total intracranial volume (z-scored)

0.081 (−0.12–0.28)

0.419

Sex (0 = male)

−0.40 (−1.31–0.51)

0.392

Hippocampal volume (z-scored)

− 0.517 (− 0.70 to − 0.34)

< 0.001

APOE ε4 genotype (0 = no ε4)

0.01 (− 0.33–0.35)

0.96

CSF Aβ/P-tau positivity (Aβ/P-tau+) (0 = not Aβ/P-tau+)

0.64 (− 0.77–2.04)

0.376

Aβ/P-tau+ × diagnosis

0.03 (− 0.54–0.60)

0.92

Aβ/P-tau+ × sex

− 1.50 (− 3.32–0.32)

0.108

Diagnosis × sex

−0.20 (− 0.65–0.26)

0.398

Aβ/P-tau+ × diagnosis × sex

1.03 (0.25–1.82)

0.01

Note: Estimates, confidence intervals, and p values were calculated for each regression model
Abbreviations: Aβ/P-tau+ amyloid beta/P-tau positive, ADAS Alzheimer’s Disease Assessment Scale, APOE apolipoprotein E, CSF cerebrospinal fluid, MMSE MiniMental State Examination

The current study did not confirm hypotheses about
sex-specific HV preservation. Previously, we have shown
in the ADNI sample that CN women with positive amyloid PET studies show no difference in total HV and subiculum subfield volume, compared to CN women with
negative amyloid PET, but that volumetric decrements
are observed in amyloid-positive women at the MCI

stage [3, 17]. Reasons for lack of replication are unclear
but could include slight differences in methodology or
sample composition, such as inclusion of CN and symptomatic groups in the present analysis as well as differences in the biomarkers used to define the presence of
proteinopathy. Lack of replication emphasizes the need
for additional research on how this structure—with

Fig. 1 Comparison of the Aβ/P-tau effect on memory in men and women. Comparison of 10 word delayed recall performance in Aβ/P-tau+ and
Aβ/P-tau− participants, stratified by sex, in a healthy controls and b patients with cognitive symptoms. Comparisons were adjusted for age and
education. Further comparison among the symptomatic patients (SCD and MCI) is shown in Additional file 1: Figure S1
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known developmental [35], aging-related [36, 37], and
neurochemical sex differences [38]—does or does not
show patterns of dysfunction and atrophy that differ by
sex in AD. In addition, this finding underscores the importance of considering other neural underpinnings of
early sex-based memory preservation and later decline.
As important context, there are known sex by APOE
ε4 interactive effects, with evidence for more deleterious
effects of APOE ε4 on cognition, hippocampal structure,
brain function at rest, and tau pathology in women than
men ([6, 39], for a recent review see [40]). The present
analysis showed that men and women did not differ in
number of APOE ε4 carriers and also controlled for effects of APOE ε4. Despite these efforts to show our findings were not driven by APOE ε4 status, adding APOE
ε4 as an interaction term was beyond the scope of the
present analysis due to limited power. Further work is
needed on how memory reserve presents over the AD
spectrum in women with APOE ε4.
Limitations of this analysis include having a smaller
sample size than studies that combine across cohorts,
which is particularly relevant when evaluating complex interactions. Although the current study in part replicates
prior work by our group [3], the challenges of complex interactions and multiple comparisons mean that wider replication is important to ensure generalizable conclusions.
Expanding the analysis to additional regions of interest
will also be important for generalizability. The sample included is also majority white, and research in diverse samples will be key to generalizing the findings to all women.
The current analysis was also cross-sectional in nature,
limiting ability to interpret memory findings as true losses
of function over time. In contrast, the present study has
strengths in that participants are more representative of
the general aging population than in some other cohorts
[18, 19], were more thoroughly assessed and diagnosed,
and have had brain imaging conducted on the same MRI
magnet.

Conclusions
In conclusion, this study shows relative preservation of
verbal memory in the presence of AD proteinopathy,
limited to women with normal cognition, and not in
women with reported or measured memory symptoms.
This resilience was specific to memory and was not
present for other cognitive functions. Future studies
should examine other potential neural sources of
sex-based early memory preservation, conduct additional multi-cohort analyses of complex sex-based
interactive
effects—including
longitudinally—and
examine the practical effects of sex differences in
memory on clinical diagnosis and clinical trial inclusion and outcomes.
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1: Figure S1. Comparison of the Aβ/P-tau effect on
memory in men and women. Comparison of 10 word delayed recall
performance in Aβ/P-tau+ and Aβ/P-tau- participants, stratified by sex, in
patients with A. subjective cognitive decline, and B. mild cognitive
symptoms.
Additional file 2: Regression Predicting Hippocampal Volumes with
Cognitively Normal, Subjective Cognitive Decline, and Mild Cognitive
Impairment Groups. This additional file contains a table summarizing the
results of a regression predicting hippocampal volumes separated by
diagnostic group.
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